Log In
Print
BCIQ
Print
Print this Print this
 

Poteligeo, mogamulizumab (AMG 761, KW-0761)

  Manage Alerts
Collapse Summary General Information
Company Kyowa Hakko Kirin Co. Ltd.
DescriptionHumanized mAb against CC chemokine receptor 4 (CCR4; CD194)
Molecular Target CC chemokine receptor 4 (CCR4) (CD194)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today